Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible...
Saved in:
Main Authors: | Amber N. Edinoff, Connor R. Swinford, Amira S. Odisho, Caroline R. Burroughs, Cain W. Stark, Walid A. Raslan, Elyse M. Cornett, Adam M. Kaye, Alan D. Kaye |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Medical Publishing
2022-11-01
|
Series: | Health Psychology Research |
Online Access: | https://doi.org/10.52965/001c.39576 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer's disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitors.
by: Fatima Zahra Guerguer, et al.
Published: (2025-01-01) -
Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review
by: Amber N. Edinoff, et al.
Published: (2022-11-01) -
Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status
by: Amber N. Edinoff, et al.
Published: (2022-08-01) -
Meta-analysis examining the association between low platelet monoamine oxidase levels and Zuckerman's sensation seeking scale in a sex dependent manner
by: Jordan Winfield, et al.
Published: (2025-02-01) -
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes
by: Amnon A. Berger, et al.
Published: (2022-06-01)